Fiche société
Shanghai Ming Ju Biotechnology Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Relma-celThis is a phase I, open-label, single-arm, multicenter study to asess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China. | SEP | Phase 1 | À vérifier | China | À vérifier |
| Relma-celThis is a phase I, open-label, single-arm, multicenter study to asess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China. | SEP | Phase 1 | À vérifier | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Relma-cel | SEP | Phase 1 | NCT05765006 | CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus | UNKNOWN |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Relma-cel | Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. | Nature communications | ||
| Relma-cel | Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. | EClinicalMedicine | ||
| Relma-cel | Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. | Blood advances |